New Doctor Proves Risk Factors for Response to Neoadjuvant Chemotherapy in Breast Cancer Patients

• Posted by: Admin
• Selasa, 30 Mei 2023
• Has been read 178 time(s)

Located in the graduate courtroom lt. III, Denpasar Postgraduate Building, the Doctoral Promotion exam has taken place with the promovendus candidate, dr. Putu Anda Tusta Adiputra, Sp.B(K)Onk., with the dissertation title "Low CD3/CD8 and CD3/CD45RO Immunoscores and High FOXP3 Expression as Risk Factors for Poor Response to Neoadjuvant Chemotherapy in Patients with Triple Negative Breast Cancer in Denpasar ." (29/5/2023)

Neoadjuvant chemotherapy (NAC) has become a standard treatment option, including in cases of triple negative breast cancer (TNBC). The immune profile of the cancer microenvironment affects the response of NAC through the role of lymphocytes. There are three markers of effector lymphocytes namely CD3, CD8 and CD45RO. The quantification score of the CD3, CD8, lymphocyte population at the center of the tumor and the invasive margins is referred to as the immunoscore (IS). Pro-tumorigenic activity can also be observed from the presence of regulatory T cells (Treg) via the forkhead box protein marker P3

(FOXP3).

Cross-sectional and case control studies were carried out at Prof. dr. I G.N.G. Ngoerah and Prima Medika Hospital from 1 August 2021 to 31 August 2022 for patients diagnosed with TNBC and who have received neoadjuvant chemotherapy. Paraffin blocks of all samples were collected. Immunohistochemical examination of CD3, CD8, and CD45RO on the central tumor and invasive margins as well as FOXP3 expression was carried out at the Anatomical Pathology Laboratory of Prof. dr. I G.N.G. goof off. Data were then analyzed bivariately and multivariately with logistic regression.

Of the 72 patients in a cross-sectional study, seven (9.7%) had a pathological complete response and 35 (48.6%) had a poor response to NAC. The conclusions obtained indicate that low CD3/CD8 immunoscore and high FOXP3 expression are independent risk factors for poor NAC response in TNBC patients.

The exam was led by the Dean of FK Unud, Dr. dr. Komang Januartha Putra Pinatih, M.Kes., with the testing team:

1. Dr. dr. Ketut Suega, Sp.PD-KHOM (Promoter)

2. Prof. Dr. dr. I.B. Tjakra Wibawa Manuaba, MPH., Sp.B(K)Onk (Co-promoter I)

3.Dr. dr. I Wayan Sudarsa, Sp.B (K) Onk (Co-promoter II)

4. Dr. dr. Sri Maliawan, Sp.BS (K), FICS

5. Prof. Dr. dr. I Wayan Putu Sutirta Yasa, M.Si

6.Dr. dr. Wira Gotera, Sp.PD-KEMD-FINASIM

7.Dr. dr. I Made Sudarmaja, M. Kes

8. Dr. dr. Gede Wirya Kusuma Duarsa, MARS, M. Kes, Sp. U, Subsp. Ped

9.Dr. dr. Ni Putu Sriwidyani, Sp.PA(K)

10.Dr. dr. I Wayan Niryana, M.Kes.,Sp.BS(K)

While academic invitations are:

1.Dr. dr. I Ketut Widiana, Sp.B (K)Onk

2.Dr. dr. Ketut Suparna, Sp.B(K)Onk, M.Sc

3.Dr. dr. Ida Bagus Made Suryawisesa, Sp.B(K)Onk

4.Dr. dr. Putu Yuliawati, Sp.M(K)

5.Dr. dr. I Gusti Ayu Putu Eka Pratiwi, M.Kes.,Sp.A(K)

In this exam, Dr. dr. Putu Anda Tusta Adiputra, Sp.B(K)Onk., was declared to have graduated as the 381st Doctor Graduate of the Doctoral Degree in Medical Sciences, Faculty of Medicine, Udayana University with the Cum Laude predicate.

Gallery